MWG Biotech intends to sell two of its four business units in an effort to refocus the company on its core businesses.

The Ebersberg, Germany-based firm said late last week that it would divest itself of its Genomic Diagnosis business, which includes its microarrays and related products, and its Genomic Technology business, which includes its lab automation products. It will retain its Genomic Synthesis unit, which manufacturers oligonucleotides, and its Genomic Information business, which provides the firm’s core DNA sequencing services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.